{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66"}],"title":"Experienced AEs"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Did not experience AEs"}],"title":"Any grade AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"62"}],"title":"Experienced AEs"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Did not experience AEs"}],"title":"AE Grade >=3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"}],"units":"Participants"}],"description":"Frequency of adverse events (AEs) reported classified by type and severity.","groups":[{"description":"Atezolizumab (1200 mg) intravenously administered every 21 days (one cycle) up to disease progression, unacceptable toxicity or absence of clinical benefit.\n\nGemcitabine 1000 mg/m2 IV on D1 and 1000 mg/m2 IV on D8 of each 21-day cycle plus Cisplatin 70 mg/m2 by IV on split-dose schedule of 35 mg/m2 on day 1 (D1) and 35 mg/m2 on day 8 (D8) for up to 6 cycles.\n\nAtezolizumab 1200 mg/m2: Fixed dose of 1200 mg/m2 by intravenous (IV) infusion on D1 of each cycle up to disease progression, unacceptable toxicity or absence of clinical benefit.\n\nGemcitabine 1000 mg/m2: Gemcitabine 1000 mg/m2 IV on D1 and 1000 mg/m2 IV on D8 of each 21-day cycle for up to 6 cycles.\n\nCisplatin 70 mg/m2: Cisplatin 70 mg/m2 by IV on split-dose schedule of 35 mg/m2 on day 1 (D1) and 35 mg/m2 on day 8 (D8) for up to 6 cycles.","id":"OG000","title":"AUREA Single-arm"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Through study completion, average 2 years","title":"Adverse Events Frequency (Safety)","type":"SECONDARY","unitOfMeasure":"Participants"}